This session will be moderated by Joff Wild, Sisvel.
This is the final session of the year-long Track 1 series addressing SEP licensing issues. The panel discussion will build on discussions this year about successful SEPs licensing, what we have learned from SEP litigation, what policy proposals are being made to streamline SEP licensing (and will they help or hinder), and finally – given the current environment – how can companies and their counsel best manage SEP licensing deals efficiently? These issues have been actively discussed this year and our panel discussion will attempt to make sense of it all!
This session will be moderated
by Gillian Fenton, GSK.
This is the final session of the year-long Track 2 series addressing Artificial Intelligence and the Life Sciences industry. The panel discussion will build on discussions this year about the use and impact of AI on regulatory issues in data collection, drug discovery and clinical trials among other topics.
This session will be co-moderated by
Tilman Müller-Stoy, Bardehle Pagenberg,
and Sam Wiley, LOT Network.
This is the final session of the year-long Track 3 series addressing Litigation Strategies in relation to the Unified Patent Court. It’s been an incredible few months watching the first filings at the UPC and this LESI team has gotten first hand reports from litigators, judges and users of the new proceedings, as well as views on what lessons the UPC can (or should) learn from U.S litigation. This final session will evaluate how the first year at the UPC is going and will speculate about the role and likely impact of the proceedings.
